This evidence suggests that the depletion of S100B in 12-month-old mice leads to a more regulatory and less cytotoxic phenotype in these animals, which may suggest a potential strategy to reduce MS-associated pathology in late-onset MS patients. This evidence concerns the gene S100B and myeloid sarcoma.